Immix Biopharma (NASDAQ:IMMX) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis (NYSE:NVS) and BeiGene's (NASDAQ:BGNE) tislelizumab to treat patients with ad... Stay informed with the latest.
Disclaimer: All resources on this site are collected from the internet. If any content infringes on your rights, please contact us and we will remove it within 24 hours.
Like 
Dislike